NasdaqGS:CRNXPharmaceuticals
Crinetics Pharmaceuticals (CRNX) Stock Looks Rich On Book Value But Reasonable On Deal Value
Crinetics Pharmaceuticals stock is coming off a very strong run, with the price up about 403.6% over the past three years, while the valuation checks now point to a company that screens as overvalued on market multiples and only scores as mixed overall.
A roughly 403.6% return over three years puts Crinetics Pharmaceuticals among the stronger performers, which raises the bar for what the current price already assumes about the future.
The agreed acquisition by Vertex Pharmaceuticals can...